CN100372938C - 编码一种癌症标记的基因 - Google Patents

编码一种癌症标记的基因 Download PDF

Info

Publication number
CN100372938C
CN100372938C CNB998061697A CN99806169A CN100372938C CN 100372938 C CN100372938 C CN 100372938C CN B998061697 A CNB998061697 A CN B998061697A CN 99806169 A CN99806169 A CN 99806169A CN 100372938 C CN100372938 C CN 100372938C
Authority
CN
China
Prior art keywords
lab
cancer
protein
cells
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998061697A
Other languages
English (en)
Chinese (zh)
Other versions
CN1301302A (zh
Inventor
詹姆斯·A·拉多舍维奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImmvaRx Inc
Original Assignee
Mission Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mission Therapeutics Inc filed Critical Mission Therapeutics Inc
Publication of CN1301302A publication Critical patent/CN1301302A/zh
Application granted granted Critical
Publication of CN100372938C publication Critical patent/CN100372938C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0071Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0071Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB998061697A 1998-03-17 1999-03-11 编码一种癌症标记的基因 Expired - Fee Related CN100372938C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/040,485 US6166176A (en) 1998-03-17 1998-03-17 Cancer marker protein and peptides thereof
US09/040,485 1998-03-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2008100031485A Division CN101260401A (zh) 1998-03-17 1999-03-11 编码一种癌症新标记的基因

Publications (2)

Publication Number Publication Date
CN1301302A CN1301302A (zh) 2001-06-27
CN100372938C true CN100372938C (zh) 2008-03-05

Family

ID=21911225

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB998061697A Expired - Fee Related CN100372938C (zh) 1998-03-17 1999-03-11 编码一种癌症标记的基因
CNA2008100031485A Pending CN101260401A (zh) 1998-03-17 1999-03-11 编码一种癌症新标记的基因

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2008100031485A Pending CN101260401A (zh) 1998-03-17 1999-03-11 编码一种癌症新标记的基因

Country Status (14)

Country Link
US (7) US6166176A (enExample)
EP (1) EP1062346B1 (enExample)
JP (2) JP2002512005A (enExample)
CN (2) CN100372938C (enExample)
AP (1) AP2000001917A0 (enExample)
AT (1) ATE337400T1 (enExample)
AU (2) AU762758B2 (enExample)
BR (1) BR9908886A (enExample)
CA (1) CA2323494A1 (enExample)
DE (1) DE69932926T2 (enExample)
EA (1) EA003735B1 (enExample)
IL (1) IL138208A0 (enExample)
OA (1) OA11487A (enExample)
WO (1) WO1999047683A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166176A (en) * 1998-03-17 2000-12-26 Immvarx, Inc. Cancer marker protein and peptides thereof
US6835370B2 (en) 1999-11-08 2004-12-28 Rhode Island Hospital Diagnosis and treatment of malignant neoplasms
US20030031670A1 (en) * 1999-11-08 2003-02-13 Jack R. Wands Diagnosis and treatment of malignant neoplasms
US20050123545A1 (en) * 1999-11-08 2005-06-09 Wands Jack R. Diagnosis and treatment of malignant neoplasms
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
US7306919B1 (en) 2001-10-31 2007-12-11 Thornthwaite Jerry T Antigen-antibody cancer recognition system
EP1536814A4 (en) * 2002-07-03 2006-02-15 Immunogen Inc ANTIBODIES AGAINST MUC1 AND MUC16 NOT RELEASED AND USES THEREOF
DE60324794D1 (de) * 2003-09-04 2009-01-02 Biomay Ag Hypoallergene Polypeptide basierend auf aus Fisch gewonnenem Parvalbumin
EP1699485A4 (en) * 2003-11-14 2007-12-19 Massachusetts Inst Technology ANTI-HYDROLYSATE ANTIBODIES AND ITS USES
CN100457922C (zh) * 2005-10-20 2009-02-04 康哲医药研究(深圳)有限公司 检测酪丝亮肽抗肝癌效果的方法及所用试剂盒与基因芯片
RU2340896C1 (ru) * 2007-05-17 2008-12-10 Негосударственное научно-исследовательское учреждение "Биомедицинский центр" Способ диагностики онкологических заболеваний
GB201002627D0 (en) 2010-02-16 2010-03-31 Loxbridge Res Llp Aptamer based analyte detection method
TW202039536A (zh) * 2018-12-13 2020-11-01 美商拉比林免疫治療美國有限公司 用於癌症免疫療法之基於拉比林(labyrinthin)之肽及其用途
JP2022517329A (ja) * 2019-01-08 2022-03-08 ラビアールエックス イミュノロジック セラピューティクス (ユーエスエー) リミテッド ラビリンチン又はその一部を標的とする構築物及びその使用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816402A (en) * 1986-01-07 1989-03-28 Northwestern University Murine hybridoma and diagnostic antibody produced thereby
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5223604A (en) * 1991-06-25 1993-06-29 S.P.I. Synthetic Peptides Incorporated Pseudomonas exoenzyme s peptide composition and method
US5728819A (en) * 1996-08-02 1998-03-17 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US5994062A (en) 1995-10-02 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Epithelial protein and DNA thereof for use in early cancer detection
US6166176A (en) * 1998-03-17 2000-12-26 Immvarx, Inc. Cancer marker protein and peptides thereof
US6344548B1 (en) * 1998-06-24 2002-02-05 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US7135617B2 (en) * 1998-07-02 2006-11-14 Calgene Llc Diacylglycerol acyl transferase proteins
US6100077A (en) * 1998-10-01 2000-08-08 The Trustees Of Columbia University In The City Of New York Isolation of a gene encoding diacylglycerol acyltransferase
US20030161831A1 (en) * 2001-02-23 2003-08-28 Sylvaine Cases Mono-and diacylglycerol acyltransferases and methods of use thereof
US7045326B2 (en) * 2001-02-23 2006-05-16 The Regents Of The University Of California Mono- and diacylglycerol acyltransferases and methods of use thereof
CA2492205A1 (en) * 2002-07-31 2004-02-05 Monsanto Technology, Llc Diacylglycerol acyltransferase nucleic acid sequences and associated products
US8685679B2 (en) * 2004-11-04 2014-04-01 E I Du Pont De Nemours And Company Acyltransferase regulation to increase the percent of polyunsaturated fatty acids in total lipids and oils of oleaginous organisms
US8507754B2 (en) * 2009-01-31 2013-08-13 University Of North Texas Engineering lipids in vegetative tissues of plants
CA2804025C (en) * 2010-06-28 2023-02-21 Commonwealth Scientific And Industrial Research Organisation Methods of producing lipids

Also Published As

Publication number Publication date
WO1999047683A1 (en) 1999-09-23
DE69932926D1 (de) 2006-10-05
US7635759B2 (en) 2009-12-22
AU2999699A (en) 1999-10-11
IL138208A0 (en) 2001-10-31
US8163883B2 (en) 2012-04-24
BR9908886A (pt) 2000-11-21
JP2002512005A (ja) 2002-04-23
CA2323494A1 (en) 1999-09-23
AU762758B2 (en) 2003-07-03
JP2009165492A (ja) 2009-07-30
EP1062346A1 (en) 2000-12-27
DE69932926T2 (de) 2007-05-24
AP2000001917A0 (en) 2000-09-30
ATE337400T1 (de) 2006-09-15
US20080249284A1 (en) 2008-10-09
US20050208508A1 (en) 2005-09-22
OA11487A (en) 2004-05-04
US20100233711A1 (en) 2010-09-16
HK1033151A1 (en) 2001-08-17
CN1301302A (zh) 2001-06-27
WO1999047683A9 (en) 1999-11-18
EA200000845A1 (ru) 2001-08-27
US20100112582A1 (en) 2010-05-06
US6727080B1 (en) 2004-04-27
US20110110963A1 (en) 2011-05-12
US6166176A (en) 2000-12-26
CN101260401A (zh) 2008-09-10
US7329743B2 (en) 2008-02-12
EP1062346B1 (en) 2006-08-23
EA003735B1 (ru) 2003-08-28
AU2003204331B2 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
US7635759B2 (en) Gene encoding labyrinthin, a marker for cancer
JP4204642B2 (ja) 前立腺に特異的な膜抗原
JP6196350B2 (ja) 診断および治療のための腫瘍関連細胞表面抗原の同定
JP5731436B2 (ja) 腫瘍診断と治療のための表面関連抗原の同定
KR20080052664A (ko) 진단 및 치료용 종양 관련 항원의 동정
JP4270523B2 (ja) 乳癌の処置および診断のための組成物および方法
JP2003512036A (ja) Tadg−15:癌において過剰発現されている細胞外セリンプロテアーゼ
KR20030090655A (ko) 암세포 증식 조절에 유용한 폴리뉴클레오티드
WO1997028193A1 (en) Compositions and methods useful in the detection and/or treatment of cancerous conditions
WO1997028193A9 (en) Compositions and methods useful in the detection and/or treatment of cancerous conditions
HK1122838A (en) A gene encoding for a novel marker for cancer
HK1033151B (en) Gene encoding labyrinthin, a marker for cancer
MXPA00008836A (en) Gene encoding labyrinthin, a marker for cancer
NZ507014A (en) A gene encoding a novel marker for cancer
JP2008289472A (ja) 乳癌の処置および診断のための組成物および方法
AU2008202039A1 (en) Gene encoding labyrinthin, a marker for cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: IMVAX CO.,LTD.

Free format text: FORMER OWNER: J.A. RADOSEVICH

Effective date: 20031104

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20031104

Address after: Illinois State

Applicant after: Immvarx Inc.

Address before: Illinois State

Applicant before: James.A. Radosevich

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080305

Termination date: 20110311